Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,187.70 +6.96 (+0.13%) Dow
38,884.26 +31.99 (+0.08%) Nasdaq
16,332.56 -16.69 (-0.10%) Bitcoin USD
63,041.25 -463.93 (-0.73%) CMC Crypto 200
1,303.68 -61.45 (-4.50%)
Swedish Orphan Biovitrum AB (publ) (B6E.F)
| Previous close | 24.08 |
| Open | 24.08 |
| Bid | 23.92 x 76000 |
| Ask | 24.24 x 74000 |
| Day's range | 23.94 - 24.18 |
| 52-week range | 16.13 - 26.46 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 8.183B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 44.33 |
| EPS (TTM) | 0.54 |
| Earnings date | 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
PR NewswireSobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
PR NewswireNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
